Enjoy complimentary customisation on priority with our Enterprise License!
Few of the key findings from this malignant mesothelioma therapeutics market analysis report are summarized below
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
The primary risk factor for malignant mesothelioma is exposure to asbestos in the form of hydrated silicates and long thin fibers. There has been significant growth in the use of asbestos in recent years in building materials, machines, and transport vehicles. People working in industries that have extensive asbestos applications are regularly exposed to the material and have higher chances of being predisposed to asbestos-related diseases. However, all individuals exposed to asbestos do not develop malignant mesothelioma as it depends on the extent and duration of the exposure. The increasing high-risk factors are contributing to the need for malignant mesothelioma therapeutics. Therefore, extensive use of asbestos in industries will drive the global malignant mesothelioma therapeutics market during the forecast period.
The increasing prevalence of malignant mesothelioma globally over the years has augmented the need for awareness initiatives to diagnose and treat the disease at earlier stages. Organizations are conducting programs to spread awareness about cancer, causing agents such as asbestos, and effective treatment options. Several screening programs have been conducted for people who are exposed to asbestos regularly to prevent the disease from progressing to advanced stages. Moreover, there is a significant unmet need for novel therapies with fewer side-effects and high efficacy. As a result, vendors are capitalizing on this factor and focusing on developing novel therapies. Therefore, the increasing awareness of malignant mesothelioma is one of the key malignant mesothelioma therapeutics trends. The trend will propel the market growth at a CAGR of about 7% during the forecast period.
The malignant mesothelioma therapeutics market is moderately fragmented. To help clients improve their market positions, this report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this report also includes information on the upcoming malignant mesothelioma therapeutics market trends and challenges that will influence market growth. This will enable companies to create strategies to make the most of future growth opportunities.
The report offers a detailed analysis of several leading malignant mesothelioma therapeutics companies, including:
The chemotherapy market segment will account for the highest market share. The demand for chemotherapy has been perpetually high for treating cancer, including malignant mesothelioma. This is because chemotherapy is a significant first-line treatment for cancer. This factor has been contributing to the growth of the market segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the malignant mesothelioma therapeutics market size.
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest share of the malignant mesothelioma therapeutics market throughout the forecast period. Factors such as the increasing prevalence of malignant mesothelioma and associated risk factors and the rising tolerance toward ALIMTA, an approved drug, are contributing to the malignant mesothelioma therapeutics market growth in North America.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.